Top

Published in:

01-01-2005 | Original Article

Beyond the Clinical Trials: How Often Is Sentinel Lymph Node Dissection Performed for Breast Cancer?

Authors: Melinda A. Maggard, MD, Karen E. Lane, MD, Jessica B. O’Connell, MD, Deepa Dharshani Nanyakkara, Clifford Y. Ko, MD, MSHS

Published in: Annals of Surgical Oncology | Issue 1/2005

Abstract

Background

Sentinel lymph node dissection (SLND) has been shown to be a reasonable treatment option for early-stage breast cancer. Until recently, SLND was limited to clinical trials. Because this technique is now offered outside of trials, its prevalence is unknown.

Methods

All patients with stage I or II breast cancer in the Surveillance, Epidemiology, and End Results national cancer registry (1998–2000) were evaluated. Data were collected for demographics, tumor characteristics, surgical resection, lymph node evaluation (SLND or complete axillary dissection), registry site, and year of diagnosis. Multivariate regression analysis was performed to identify predictors for receiving SLND.

Results

A total of 54,772 patients diagnosed with breast cancer had undergone surgical lymph node evaluation; 27.2% patients with stage I disease underwent SLND, as compared with 22.7% for stage II. Older patients and minority groups were less likely to receive SLND. Receipt of SLND varied by registry site (7.9%–32.7%). Multivariate regression showed that older patients had lower odds of receiving SLND (60–69 years: odds ratio, .73; P < .0001) as compared with younger patients. Additionally, blacks, Hispanics, and Asians had lower odds of receiving SLND (odds ratio of .64, .58, and .80, respectively; P < .0001). SLND use increased over the 3 years in the study (P < .0001).

Conclusions

This population-based analysis showed relatively infrequent use of SLND for early-stage breast cancer. These results suggest a slow transition of this procedure from clinical trials into the community. Future work should be targeted at improving the rate at which patients receive this procedure, particularly for elderly and minority groups and low-use regions.

Giuliano, AE, Kirgan, DM, Guenther, JM, et al. 1994Lymphatic mapping and sentinel lymphadenectomy for breast cancerAnn Surg2203918discussion 398–401PubMed

Veronesi, U, Paganelli, G, Viale, G, et al. 2003A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancerN Engl J Med34954653CrossRefPubMed

Krag, D, Weaver, D, Ashikaga, T, et al. 1998The sentinel node in breast cancer—a multicenter validation studyN Engl J Med3399416CrossRefPubMed

Giuliano, AE, Dale, PS, Turner, RR, et al. 1995Improved axillary staging of breast cancer with sentinel lymphadenectomyAnn Surg2223949discussion 399–401

Guenther, JM, Krishnamoorthy, M, Tan, LR 1997Sentinel lymphadenectomy for breast cancer in a community managed care settingCancer J Sci Am333640PubMed

Martin, RC,II, Edwards, MJ, Wong, SL, et al. 2000Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study GroupSurgery12813944

Peintinger, F, Reitsamer, R, Stranzl, H, et al. 2003Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patientsBr J Cancer8964852

Golshan, M, Martin, WJ, Dowlatshahi, K 2003Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissectionAm Surg6920911discussion 212

Roumen, RM, Kuijt, GP, Liem, IH, et al. 2001Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissectionBr J Surg88163943CrossRefPubMed

Cox, CE, Salud, CJ, Cantor, A, et al. 2001Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysisJ Am Coll Surg193593600

McMasters, KM, Wong, SL, Chao, C, et al. 2001Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniquesAnn Surg2342929discussion 299–300CrossRefPubMed

Edge, SB, Niland, JC, Bookman, MA, et al. 2003Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centersJ Natl Cancer Inst95151421

Lucci, A,Jr, Kelemen, PR, Miller, C,III, Chardkoff, L, Wilson, L 2001National practice patterns of sentinel lymph node dissection for breast carcinomaJ Am Coll Surg1924538

Ross, MI 2001Sentinel node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USAAnn Surg Oncol877S81S

Krag, DN, Harlow, S 2003Current status of sentinel node surgery in breast cancerOncology (Huntingt)1716636

North American Association of Central Cancer Registries. Available at: http://www.naaccr.org. 2003. Accessed March 18, 2004

Zippin, C, Lum, D, Hankey, BF 1995Completeness of hospital cancer case reporting from the SEER Program of the National Cancer InstituteCancer76234350

Title: Beyond the Clinical Trials: How Often Is Sentinel Lymph Node Dissection Performed for Breast Cancer?
Authors: Melinda A. Maggard, MD
Karen E. Lane, MD
Jessica B. O’Connell, MD
Deepa Dharshani Nanyakkara
Clifford Y. Ko, MD, MSHS
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1007/s10434-004-1168-y

At a glance: The STEP trials

Springer Medicine

Beyond the Clinical Trials: How Often Is Sentinel Lymph Node Dissection Performed for Breast Cancer?

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2005

Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin

Simplification of Breast Cancer Surgery

Extent of Thyroidectomy Is Not a Major Determinant of Survival in Low- or High-Risk Papillary Thyroid Cancer

Axillary Recurrence After Sentinel Node Biopsy

A Predictive Model for the Development of Hormone-Responsive Breast Cancer

“Axillary Recurrence After a Negative Sentinel Node Biopsy”: Editorial Comment